NAD+ Anti-Aging Supplements: Promise and Cancer Risk

A Nature Aging paper published March 2026 brought 25+ scientists from five countries together to map the state of NAD+ research — the molecule at the centre of the anti-aging supplement boom. Their conclusion: NAD+ precursors like NMN and NR show early promise in clinical trials for memory, metabolism, and muscle function, but we don't yet know the right doses, long-term safety, or who responds best. The same month, Tokyo researchers showed the closely related anti-aging compounds called polyamines can fuel cancer through a different molecular pathway than the one that supports healthy cells.

That's the tension nobody selling you a $50 bottle of NMN wants to talk about.

The Molecule Everyone's Buying

NAD+ is a coenzyme present in every cell. It helps convert food into energy, repairs DNA, and keeps mitochondria functional. Your body makes plenty of it when you're young. By middle age, levels drop — in some tissues by more than 50%. That decline tracks with memory loss, weaker muscles, and higher disease risk.

The supplement industry spotted the opportunity. The global NMN market alone is worth an estimated $400 million in 2026, projected to nearly triple by 2035. NAD+ products broadly — including NR, NMN, and direct NAD+ — sit in a market valued at $3.5 billion and growing at 15% annually. IV drips, pills, powders, and "longevity stacks" are everywhere from Brentwood wellness clinics to Amazon bestseller lists.

Celebrities get NAD+ infusions on camera. TikTok doctors explain "mitochondrial boosting" in 30-second clips. The cultural message is clear: the science is settled. It isn't.

What 25 Scientists Actually Said

The Nature Aging expert review, led by researchers at the University of Oslo and Akershus University Hospital with co-authors from Harvard Medical School, the Buck Institute for Research on Aging, Chiba University in Japan, and the University of Copenhagen, is the closest thing to a scientific consensus on NAD+ that exists.

Their findings are genuinely encouraging — with a massive caveat.

In early clinical trials, NAD+ precursors like NR and NMN doubled circulating NAD+ levels in blood within 14 days. Some participants showed improvements in skeletal muscle insulin sensitivity. Others reported better physical function and metabolic health markers. The compounds appear well-tolerated in studies lasting up to two years.

But lead author Dr. Jianying Zhang put it plainly: "To truly unlock its potential, we need to better understand the right doses, long-term safety, and interindividual variability in response to NAD+ augmentation strategies." Senior author Dr. Evandro Fei Fang-Stavem was more direct about why this paper exists now: "There is still confusion and noise in the field about which supplements work best and how they should be used."

Translation: the people who know most about this molecule think the supplement market is running years ahead of the evidence.

The Cancer Problem Nobody Resolved

Three weeks before the Oslo consensus landed, a separate team at Tokyo University of Science published findings in the Journal of Biological Chemistry that crystallise a worry longevity researchers have quietly held for years.

The question is simple. NAD+ powers all cells. Cancer cells need enormous amounts of energy to grow. If you flood your body with a molecule that supercharges cellular energy production, do you also supercharge tumours?

The Tokyo team, led by Associate Professor Kyohei Higashi, studied polyamines — anti-aging compounds closely related to the NAD+ pathway. Using high-resolution proteomic analysis of more than 6,700 proteins, they found that polyamines primarily boost glycolysis (fast glucose-to-energy conversion) in cancer cells rather than enhancing mitochondrial respiration (the process linked to healthy aging). The same family of molecules uses different cellular machinery depending on whether the tissue is healthy or cancerous.

The key distinction involves two nearly identical proteins: eIF5A1 and eIF5A2. They share 84% of their amino acid sequence. In healthy tissue, eIF5A1 activates mitochondria through autophagy — the cellular cleanup process linked to longevity. In cancer tissue, eIF5A2 drives aggressive tumour growth through glycolysis. As Dr. Higashi explained: "The biological activity of polyamines via eIF5A differs between normal and cancer tissues."

Cleveland Clinic's Dr. Hill put the clinical concern bluntly: "Cancer cells use a lot of energy to grow. There's concern that trying to increase energy production by using NAD supplements could potentially support the growth of cancer cells."

No human study has proven that NAD+ supplements cause cancer. But no long-term study has ruled it out either. The theoretical risk isn't fringe — it's acknowledged by every serious researcher in the field, including the authors of the Oslo consensus.

The Regulation Gap

The regulatory story makes the evidence gap worse.

In 2022, the FDA banned NMN as a supplement, arguing it was being investigated as a drug and therefore couldn't be sold as a dietary product. The supplement industry erupted. In September 2025, the FDA reversed course, confirming NMN could be legally marketed as a supplement again.

That reversal didn't come with new safety requirements. Independent testing by ConsumerLab has found NMN products on the market with purity levels as low as 80% — meaning up to one-fifth of what consumers swallow isn't what the label says. China, the world's largest NMN producer, hasn't approved it as a food ingredient at all. The EU treats it cautiously under novel food regulations.

The result: a $400 million global market where the product is legal in the US, banned in some forms in China, and cautiously regulated in Europe. Consumers in different countries face completely different access — and completely different risk profiles — for the same compound.

What This Means for Anyone Taking NAD+ Supplements

The honest summary from the best available evidence:

NMN and NR reliably raise blood NAD+ levels. That's proven. Some early trials show benefits for insulin sensitivity and physical function. That's promising. No human trial has shown these supplements extend lifespan or reverse aging. That's the gap. The cancer concern remains theoretical but unresolved. That's the risk.

The Oslo consensus paper isn't against NAD+ supplementation. It's a call for the research to catch up with the market. Larger trials. Longer follow-ups. Better understanding of who benefits, at what dose, and — critically — who might be harmed.

If you're already taking NMN or NR, the current evidence doesn't suggest you should panic. If you're considering starting, the scientists who know this molecule best are telling you something the supplement ads won't: we don't know enough yet.

The gap between what a blood test can predict about your longevity and what a supplement can change about it remains enormous. So does the gap between what the Klotho protein shows in lab mice and what any pill delivers in humans. The longevity field is real science moving at real speed. The market just moves faster.

That $50 bottle of NMN might be the future of medicine. Or it might be the most expensive placebo of the decade. The 25 scientists who published in Nature Aging this month are trying to figure out which. Maybe give them time.